AGGRAVATION OF EPILEPSY ON LEVETIRACETAM THERAPY: 28 CLINICAL OBSERVATIONS, RISK FACTORS AND POSSIBILITY OF PROPHYLACTIC
https://doi.org/10.17650/2073-8803-2014-9-1-5-22
Abstract
The authors had properly analyzed 28 clinical cases of epilepsy aggravation on levetiracetam therapy in pediatric patients receiving levetiracetam (n = 183). Risk of aggravation was 15,3 % (n = 28), including aggravation of epileptic status in 3,3 % of cases (n = 6). Levetiracetam could aggravate the following types of epileptic seizures: predominantly tonic spasms and myoclonic seizures, atypical absences with addition of negative epileptic myoclonus de novo, rarely – focal seizures and generalized tonic-clonic seizures and in some cases could aggravate status epilepticus of atypical absences, myoclonic, hemiconvulsive, tonic-autonomic and generalized tonic-clonic seizures. So, levetiracetam in population of infancy, early childhood and pre-school age children (before 7 years) must be used very carefully in consideration of potential risk of epilepsy aggravation.
About the Authors
A. A. Kholin
Department of Child Neurology, Neurosurgery and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
Psycho-Neurology Department N 2, Russian Children Clinical Hospital, Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
I. D. Fedonyuk
Psycho-Neurology Department N 2, Russian Children Clinical Hospital, Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
L. M Kolpakchi
Psycho-Neurology Department N 2, Russian Children Clinical Hospital, Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
E. S. Il`ina
Psycho-Neurology Department N 2, Russian Children Clinical Hospital, Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
K. Yu. Mukhin
Svt. Luka’s Institute of Child Neurology & Epilepsy, Moscow
Russian Federation
Russian Federation
References
1. Белоусова Е.Д. Кеппра в рациональной политерапии эпилепсии у детей. Рус мед журн 2008;16(4):192–4.
2. Воронкова К.В., Петрухин А.С., Пылаева О.А., Холин А.С. Рациональная антиэпилептическая фармакология. Руководство для врачей. М.: Бином, 2008. 192 с.
3. Мухин К.Ю. Идиопатическая фокальная эпилепсия с псевдогенерализованными приступами – особая форма эпилепсии в детском возрасте. Рус журн дет неврол 2009;4(2):3–19.
4. Мухин К.Ю. Доброкачественные эпилептиформные нарушения детского возраста и их специфичность. В кн.: Мухин К.Ю., Петрухин А.С., Глухова Л.Ю. Эпилепсия: атлас электро-линической диагностики. М.: Альварес Паблишинг, 2004. С. 277–88.
5. Мухин К.Ю., Головтеев А.Л. Приобретенный эпилептический лобный синдром. Рус журн дет неврол 2008;3(1):21–9.
6. Мухин К.Ю., Пилия С.В., Чадаев В.А. и др. Кеппра в лечении эпилепсии: эффективность и переносимость. Журн неврол психиатр им. С.С. Корсакова 2005;105(1):49–51.
7. Atefy R., Tettenborn B. Nonconvulsive status epilepticus on treatment with levetiracetam. Epilepsy Behav 2005;6(4):613–6.
8. Ben-Menachem E., Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000;41(10):1276–83.
9. Betts T., Waegemans T., Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000;9(2):80–7.
10. Caraballo R.H., Cersósimo R., De los Santos C. Levetiracetam-induced seizure aggravation associated with continuous spikes and waves during slow sleep in children with refractory epilepsies. Epileptic Disord 2010;12(2):146–50.
11. Cereghino J.J., Biton V., Abou-Khalil B. et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55(2):236–42.
12. De Los Reyes E.C., Sharp G.B., Williams J.P., Hale S.E. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol 2004;30(4):254–6.
13. Eue S., Grumbt M., Müller M., Schulze A. Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. Epilepsy Behav 2009;15(4):467–9.
14. French J.A., Tonner F. Levetiracetam. In: Shorvon S., Perucca E., Engel J.Jr. et al. The treatment of epilepsy. 3rd ed. Oxford: Willey-Blackwell, 2009:559–73.
15. Giroux P.C., Salas-Prato M., Théorêt Y., Carmant L. Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy. Seizure 2009;18(8):559–63.
16. Glauser T.A., Ayala R., Elterman R.D. et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006;66(11):1654–60.
17. Gomer B., Wagner K., Frings L. et al. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 2007;10(3):486–94.
18. Goraya J.S., Khurana D.S., Valencia I. et al. Intravenous levetiracetam in children with epilepsy. Pediatr Neurol 2008;38(3):177–80.
19. Grosso S., Franzoni E., Coppola G. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. Seizure 2005;14(4):248–53.
20. Haberlandt E., Sigl S.B., Scholl-Buergi S. et al. Levetiractam in the treatment of two children with myoclonic status epilepticus. Eur J Paediatr Neurol 2009;13(6):546–9.
21. Kirmani B.F., Crisp E.D., Kayani S., Rajab H. Role of intravenous levetiracetam in acute seizure management of children. Pediatr Neurol 2009;41(1):37–9.
22. Kossoff E.H., Los J.G., Boatman D.F. A pilot study transitioning children onto levetiracetam monotherapy to improve language dysfunction associated with benign rolandic epilepsy. Epilepsy Behav 2007;11(4):514–7.
23. Labate A., Colosimo E., Gambardella A. et al. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 2006;15(3):214–8.
24. Lawlor K.M., Devlin A.M. Levetiracetam in the treatment of infantile spasms. Eur J Paediatr Neurol 2005;9(1):19–22.
25. Magaudda A., Gelisse P., Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 2004;45(6):678–81.
26. Mandelbaum D.E., Bunch M., Kugler S.L. et al. Efficacy of levetiracetam at 12 months in children classified by seizure type, cognitive status, and previous anticonvulsant drug use. J Child Neurol 2005;20(7):590–4.
27. Mikati M.A., El Banna D., Sinno D., Mroueh S. Response of infantile spasms to levetiracetam. Neurology 2008;70(7):574–5.
28. Opp J., Tuxhorn I., May T. et al. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany Seizure 2005;14(7):476–84.
29. Otoul С., De Smedt H., Stockis A. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia 2007;48(11):2111–5.
30. Panayiotopoulos С.P. The Epilepsies. Seizures, Syndromes and Management. Oxfordshire (UK): Bladon Medical Publishing, 2005.
31. Papacostas S., Kkolou E., Papathanasiou E. Levetiracetam in three cases of progressive myoclonus epilepsy. Pharm World Sci 2007;29(3):164–6.
32. Peake D., Mordekar S., Gosalakkal J. et al. Retention rate of levetiracetam in children with intractable epilepsy at 1 year. Seizure 2007:16(2):185–9.
33. Reiter P.D., Huff A.D., Knupp K.G., Valuck R.J. Intravenous levetiracetam in the management of acute seizures in children. Pediatr Neurol 2010;43(2):117–21.
34. Somerville E.R. Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials? Neurology 2002;59(1):79–83.
35. Verrotti A., Coppola G., Manco R. et al. Levetiracetam monotherapy for children and adolescents with benign rolandic seizures Seizure 2007;16(3):271–5.
36. von Stülpnagel C., Kluger G., Leiz S., Holthausen H. Levetiracetam as add-on therapy in different subgroups of "benign" idiopathic focal epilepsies in childhood. Epilepsy Behav 2010; 17(2):193–8.
37. Wang S.B., Weng W.C., Fan P.C., Lee W.T. Levetiracetam in continuous spike waves during slow-wave sleep syndrome. Pediatr Neurol 2008;39(2):85–90.
Review
For citations:
Kholin A.A., Fedonyuk I.D., Kolpakchi L.M., Il`ina E.S., Mukhin K.Yu. AGGRAVATION OF EPILEPSY ON LEVETIRACETAM THERAPY: 28 CLINICAL OBSERVATIONS, RISK FACTORS AND POSSIBILITY OF PROPHYLACTIC. Russian Journal of Child Neurology. 2014;9(1):5-22. (In Russ.) https://doi.org/10.17650/2073-8803-2014-9-1-5-22
Views:
1547
Email this article 